Edgar Filing: CHARLES RIVER LABORATORIES INTERNATIONAL INC

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q


ý		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED JUNE 26, 2010
OR
o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM to

Commission file number 001-15943

CHARLES RIVER LABORATORIES
INTERNATIONAL, INC.

(Exact Name of Registrant as specified in its Charter)


DELAWARE (State of Incorporation)		06-1397316 (I.R.S. Employer Identification No.)

251 BALLARDVALE STREET, WILMINGTON, MASSACHUSETTS 01887
(Address of Principal Executive Offices) (Zip Code)

781-222-6000
(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No o

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (check one):


Large accelerated filer ý		Accelerated filer o		Non-accelerated filer o (Do not check if a smaller reporting company)		Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No ý

As of July 15, 2010, there were 66,259,289 shares of the registrant's common stock outstanding.

Table of Contents

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

FORM 10-Q

For the Quarterly Period Ended June 26, 2010

Table of Contents



Part I.	Financial Information
	Item 1.	Financial Statements
		Condensed Consolidated Statements of Operations (Unaudited) for the three months ended June 26, 2010 and June 27, 2009	4
		Condensed Consolidated Statements of Operations (Unaudited) for the six months ended June 26, 2010 and June 27, 2009	5
		Condensed Consolidated Balance Sheets (Unaudited) as of June 26, 2010 and December 26, 2009	6
		Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 26, 2010 and June 27, 2009	7
		Condensed Consolidated Statement of Changes in Equity (Unaudited) for the six months ended June 26, 2010	8
		Notes to Condensed Consolidated Interim Financial Statements	9
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	29
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	38
	Item 4.	Controls and Procedures	39
Part II.	Other Information
	Item 1A.	Risk Factors	40
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	40
	Item 6.	Exhibits	41

Table of Contents

Special Note on Factors Affecting Future Results

This Quarterly Report on Form 10-Q contains forward-looking statements regarding future events and the future results of Charles River Laboratories International, Inc. (Charles River) that are based on current expectations, estimates, forecasts, and projections about the industries in which Charles River operates and the beliefs and assumptions of our management. Words such as "expect," "anticipate," "target," "goal," "project," "intend," "plan," "believe," "seek," "estimate," "will," "likely," "may," "designed," "would," "future," "can," "could" and other similar expressions that are predictions of or indicate future events and trends or which do not relate to historical matters are intended to identify such forward-looking statements. These statements are based on current expectations and beliefs of Charles River and involve a number of risks, uncertainties, and assumptions that are difficult to predict. For example, we may use forward-looking statements when addressing topics such as: future demand for drug discovery and development products and services, including the outsourcing of these services; present spending trends and other cost reduction activities by our customers (particularly in light of the challenging economic environment); future actions by our management; the outcome of contingencies; changes in our business strategy; changes in our business practices and methods of generating revenue; the development and performance of our services and products; market and industry conditions, including competitive and pricing trends; changes in the composition or level of our revenues; our cost structure; the impact of acquisitions and dispositions; the timing of the opening of new and expanded facilities; our expectations with respect to sales growth and operating synergies (including the impact of specific actions intended to cause related improvements); the impact of specific actions intended to improve overall operating efficiencies and profitability (including without limitation our Lean Sigma Six program and our ERP project); changes in our expectations regarding future stock option, restricted stock, and other equity grants to employees and directors; changes in our expectations regarding our stock repurchases; expectations with respect to foreign currency exchange; assessing (or changing our assessment of) our tax positions for financial statement purposes; and our cash flow and liquidity. In addition, these statements include the impact of economic and market conditions on our customers; the effects of our 2009 and 2010 cost-saving actions and other actions designed to manage expenses, operating costs and capital spending and to streamline efficiency (including the expected impact of the suspension of our PCS Massachusetts operations); the timing of our repatriation of accumulated income earned outside the United States and the ability of Charles River to withstand the current market conditions. You should not rely on forward-looking statements because they are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document or in the case of statements incorporated by reference, on the date of the document incorporated by reference. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K for the year ended December 26, 2009 under the section entitled "Our Strategy," the section entitled "Risks Related to Our Business and Industry," the section of this Quarterly Report on Form 10-Q entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and in our press releases and other financial filings with the Securities and Exchange Commission. We have no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or risks. New information, future events or risks may cause the forward-looking events we discuss in this report not to occur.

Table of Contents

Part I. Financial Information

Item 1. Financial Statements

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(dollars in thousands, except per share amounts)

		Three Months Ended

		June 26, 2010			June 27, 2009
Net sales related to products		$	115,333		$	118,474
Net sales related to services			176,771			189,685

Total net sales			292,104			308,159
Costs and expenses
	Cost of products sold		62,655			64,419
	Cost of services provided		129,085			129,277
	Selling, general and administrative		66,127			56,582
	Amortization of intangibles		6,033			7,219

Operating income			28,204			50,662
Other income (expense)
	Interest income		262			409
	Interest expense		(7,105	)		(5,351	)
	Other, net		(736	)		1,565

Income before income taxes			20,625			47,285
Provision for income taxes			6,530			13,630

Net income			14,095			33,655
	Less: Net loss attributable to noncontrolling interests		(359	)		(499	)

Net income attributable to common shareowners		$	14,454		$	34,154

Earnings per common share
	Basic	$	0.22		$	0.53
	Diluted	$	0.22		$	0.52

See Notes to Condensed Consolidated Interim Financial Statements

Table of Contents

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(dollars in thousands, except per share amounts)

		Six Months Ended

		June 26, 2010			June 27, 2009
Net sales related to products		$	236,384		$	235,384
Net sales related to services			353,065			374,301

Total net sales			589,449			609,685
Costs and expenses
	Cost of products sold		126,378			127,752
	Cost of services provided		262,790			259,250
	Selling, general and administrative		129,368			118,760
	Amortization of intangibles		13,207			13,368

Operating income			57,706			90,555
Other income (expense)
	Interest income		659			1,038
	Interest expense		(13,112	)		(10,584	)
	Other, net		(1,147	)		1,303

Income before income taxes			44,106			82,312
Provision for income taxes			13,011			23,788

Net income			31,095			58,524
	Less: Net loss attributable to noncontrolling interests		(741	)		(1,035	)

Net income attributable to common shareowners		$	31,836		$	59,559

Earnings per common share
	Basic	$	0.49		$	0.91
	Diluted	$	0.48		$	0.91

See Notes to Condensed Consolidated Interim Financial Statements

Table of Contents

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(dollars in thousands, except per share amounts)

				June 26, 2010			December 26, 2009

Assets
	Current assets
		Cash and cash equivalents		$	219,077		$	182,574
		Trade receivables, net			218,695			196,947
		Inventories			96,571			102,723
		Other current assets			73,705			113,357

			Total current assets		608,048			595,601
	Property, plant and equipment, net				837,580			865,743
	Goodwill, net				500,585			508,235
	Other intangibles, net				144,025			160,292
	Deferred tax asset				12,926			18,978
	Other assets				53,473			55,244

			Total assets	$	2,156,637		$	2,204,093

Liabilities and Equity
	Current liabilities
		Current portion of long-term debt and capital leases		$	26,774		$	35,413
		Accounts payable			29,681			31,232
		Accrued compensation			49,215			45,522
		Deferred revenue			61,651			72,390
		Accrued liabilities			59,570			49,997
		Other current liabilities			19,169			15,219

			Total current liabilities		246,060			249,773
	Long-term debt and capital leases				409,441			457,419
	Other long-term liabilities				107,119			123,077

			Total liabilities		762,620			830,269
	Commitments and contingencies
	Shareowners' equity
		Preferred stock, $0.01 par value; 20,000,000 shares authorized; no shares issued and outstanding			—			—
		Common stock, $0.01 par value; 120,000,000 shares authorized; 77,567,584 issued and 66,259,329 shares outstanding at June 26, 2010 and 77,106,847 issued and 65,877,218 shares outstanding at December 26, 2009			776			771
		Capital in excess of par value			2,055,641			2,038,455
		Accumulated deficit			(206,657	)		(238,493	)
		Treasury stock, at cost, 11,308,255 shares and 11,229,629 shares at June 26, 2010 and December 26, 2009, respectively			(473,492	)		(470,527	)
		Accumulated other comprehensive income			20,200			45,037

			Total shareowners' equity		1,396,468			1,375,243

	Noncontrolling interests				(2,451	)		(1,419	)

			Total equity		1,394,017			1,373,824

			Total liabilities and equity	$	2,156,637		$	2,204,093

See Notes to Condensed Consolidated Interim Financial Statements

Table of Contents

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(dollars in thousands)

			Six Months Ended

			June 26, 2010			June 27, 2009
Cash flows relating to operating activities
	Net income		$	31,095		$	58,524
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities:
	Depreciation and amortization			47,851			44,870
	Non-cash compensation			14,672			12,133
	Deferred tax			1,755			11,147
	Other, net			9,104			7,929
Changes in assets and liabilities:
	Trade receivables			(29,654	)		3,569
	Inventories			3,843			778
	Other assets			(4,163	)		(3,620	)
	Accounts payable			410			(5,158	)
	Accrued compensation			5,598			(4,057	)
	Deferred revenue			(10,739	)		(11,765	)
	Accrued liabilities			10,159			(6,045	)
	Other liabilities			3,865			(1,007	)

		Net cash provided by operating activities		83,796			107,298

Cash flows relating to investing activities
	Acquisition of businesses, net of cash acquired			—			(51,161	)
	Capital expenditures			(17,725	)		(45,062	)
	Purchases of investments			(17,503	)		(54,332	)
	Proceeds from sale of investments			56,544			—
	Other, net			2,172			1,526

		Net cash provided by (used in) investing activities		23,488			(149,029	)

Cash flows relating to financing activities
	Proceeds from long-term debt and revolving credit			1,465			18,000
	Payments on long-term debt, capital lease obligation and revolving credit agreement			(63,733	)		(17,320	)
	Purchase of treasury stock			(2,965	)		(45,164	)
	Other			2,029			54

		Net cash used in financing activities		(63,204	)		(44,430	)

Effect of exchange rate changes on cash and cash equivalents				(7,577	)		(2,625	)

Net change in cash and cash equivalents				36,503			(88,786	)
Cash and cash equivalents, beginning of period				182,574			243,592

Cash and cash equivalents, end of period			$	219,077		$	154,806

Supplemental cash flow information
	Capitalized interest		$	—		$	1,490

See Notes to Condensed Consolidated Interim Financial Statements

Table of Contents

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (UNAUDITED)

(dollars in thousands)

				Total			Accumulated Deficit			Accumulated Other Comprehensive Income			Common Stock		Capital in Excess of Par			Treasury Stock			Noncontrolling Interest

	Balance at December 26, 2009			$	1,373,824		$	(238,493	)	$	45,037		$	771	$	2,038,455		$	(470,527	)	$	(1,419	)
	Components of comprehensive income, net of tax:
		Net income			31,095			31,836			—			—		—			—			(741	)
		Foreign currency translation adjustment			(25,570	)		—			(25,549	)		—		—			—			(21	)
		Amortization of pension, net gain/loss and prior service cost			177			—			177			—		—			—			—
		Unrealized loss on marketable securities			535			—			535			—		—			—			—

			Total comprehensive income	$	6,237			—			—			—		—			—		$	(762	)
	Dividends paid noncontrolling interest				(270	)		—			—			—		—			—			(270	)
	Tax detriment associated with stock issued under employee compensation plans				(140	)		—			—			—		(140	)		—			—
	Issuance of stock under employee compensation plans				2,659			—			—			5		2,654			—			—
	Acquisition of treasury shares				(2,965	)		—			—			—		—			(2,965	)		—
	Stock-based compensation				14,672			—			—			—		14,672			—			—

Balance at June 26, 2010				$	1,394,017		$	(206,657	)	$	20,200		$	776	$	2,055,641		$	(473,492	)	$	(2,451	)

See Notes to Condensed Consolidated Interim Financial Statements

Table of Contents

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS

(dollars in thousands, except per share amounts)

1. Basis of Presentation

The condensed consolidated interim financial statements are unaudited, and certain information and footnote disclosures related thereto normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been omitted in accordance with Rule 10-01 of Regulation S-X. In the opinion of management, the accompanying unaudited condensed consolidated financial statements were prepared following the same policies and procedures used in the preparation of the audited financial statements and reflect all adjustments (consisting of normal recurring adjustments) considered necessary to state fairly the financial position and results of operations of Charles River Laboratories International, Inc. The results of operations for the interim periods are not necessarily indicative of the results for the entire fiscal year. These condensed consolidated financial statements should be read in conjunction with our Annual Report on Form 10-K for the year ended December 26, 2009.

2. Restructuring and Contract Termination Costs

We implemented headcount reductions to improve operating efficiency and profitability at various sites including Shrewsbury, Massachusetts in the first quarter of 2010 and Arkansas during 2009. As of June 26, 2010, $4,608 was included in accrued compensation and $946 in other long-term liabilities on our consolidated balance sheet related to these actions.

During the first six months of 2010, we recorded severance charges of $4,815 related to the suspension of operations at our Preclinical Services facility in Shrewsbury, Massachusetts, of which $4,440 is included in cost of sales and $375 in selling, general and administrative expense. At this time we do not anticipate an asset impairment on the Shrewsbury facility. Additionally, we recorded an impairment related to our Arkansas facility by $986 in the first quarter of 2010.

		Six Months Ended

Severance and Retention Costs		June 26, 2010			June 27, 2009
Beginning balance		$	4,496		$	639
Expense			4,815			8,812
Payments/utilization			(3,757	)		(4,082	)

	Ending balance	$	5,554		$	5,369

3. Supplemental Balance Sheet Information

The composition of trade receivables is as follows:

		June 26, 2010			December 26, 2009

Customer receivables		$	187,916		$	169,354
Unbilled revenue			35,977			32,595

Total			223,893			201,949
Less allowance for doubtful accounts			(5,198	)		(5,002	)

	Net trade receivables	$	218,695		$	196,947

Table of Contents

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

(dollars in thousands, except per share amounts)

3. Supplemental Balance Sheet Information (Continued)

Depreciation is calculated using a straight-line method based on estimated useful lives of the assets. Computer hardware and software is depreciated over 3 to 8 years. Depreciation expense for the six months ended June 26, 2010 and June 27, 2009 was $34,643 and $31,503, respectively.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

The amortized cost, gross unrealized gains, gross unrealized losses and fair value for marketable securities by major security type were as follows:

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

As of June 26, 2010, we held $16,545 in auction rate securities which are variable rate debt instruments, which bear interest rates that reset approximately every 7 or 35 days. The auction rate securities owned were rated AAA by a major credit rating agency and are either commercially insured or guaranteed by the Federal Family Education Loan Program (FFELP). The underlying securities have contractual maturities which are generally greater than ten years. The auction rate securities are classified as available for sale and are recorded at fair value. Typically, the carrying value of auction rate securities approximates fair value due to the frequent resetting of the interest rates. In June, we received notice of a full call redemption on one of our auction rate securities at par value to occur in July 2010 in the amount of $5,500. As a result, we classified this auction security as short term. We have classified the other auction rate securities investments as long-term consistent with the term of the underlying security which are structured with short term interest rate reset dates of 35 days, but with contractual maturities that are long-term.

We hold cash equivalents, investments and certain other assets that are carried at fair value. We generally determine fair value using a market approach based on quoted prices of identical instruments when available. When market quotes of identical instruments are not readily accessible or available, we determine fair value based on quoted market prices of similar instruments.

The valuation hierarchy for disclosure of the inputs used to measure fair value prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable for the asset or liability, including interest rates,

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

yield curves and credit risks, or inputs that are derived principally from or corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. A financial asset or liability's classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Assets and liabilities measured at fair value on a recurring basis are summarized below:

Descriptions of the valuation methodologies used for assets and liabilities measured at fair value are as follows:

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

The table below presents a reconciliation for all assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the six months ended June 26, 2010 and June 27, 2009.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

The following table displays goodwill and other intangible assets not subject to amortization and other intangible assets that continue to be subject to amortization:

The changes in the gross carrying amount and accumulated amortization of goodwill are as follows:

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

The interest rates applicable to term loans and revolving loans under the credit agreement are, at our option, equal to either the base rate (which is the higher of the prime rate or the federal funds rate plus 0.50%) or the adjusted LIBOR rate plus an interest rate margin based upon our leverage ratio. Based on our leverage ratio, the margin range for LIBOR-based loans is 0.625% to 0.875%. As of June 26, 2010, the interest rate margin was 0.75%. The book value of our term and revolving loans approximates fair value.

We pledged the stock of certain subsidiaries as well as certain U.S. assets for our credit agreements. In addition, credit agreements include certain customary representations and warranties, events of default, notice of material adverse change to our business and negative and affirmative covenants including the ratio of consolidated earnings before interest, taxes, depreciation and amortization to consolidated interest expense, for any period of four consecutive fiscal quarters, of no less than 3.5 to 1.0 as well as the ratio of consolidated indebtedness to consolidated earnings before interest, taxes, depreciation and amortization for any period of four consecutive fiscal quarters, of no more than 3.0 to 1. As of June 26, 2010, we were compliant with all financial covenants specified in the credit agreement. We had $4,575 outstanding under letters of credit as of June 26, 2010.

Our $350,000 of 2.25% Convertible Senior Notes (the 2013 Notes) due in June 2013 with interest payable semi-annually are convertible into cash for the principal amount and shares of our common stock for the conversion premium (or, at our election, cash in lieu of some or all of such common

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

stock), if any, based on an initial conversion rate, subject to adjustment, of 20.4337 shares of our common stock per $1,000 principal amount of notes (which represents an initial conversion price of $48.94 per share), only in the following circumstances and to the following extent: (1) during any fiscal quarter beginning after July 1, 2006 (and only during such fiscal quarter), if the last reported sale price of our common stock for at least 20 trading days in the period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter is more than 130% of the conversion price on the last day of such preceding fiscal quarter; (2) during the five business-day period after any five consecutive trading-day period, or the measurement period, in which the trading price per note for each day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate on each such day; (3) upon the occurrence of specified corporate transactions, as described in the indenture for the 2013 Notes; and (4) at the option of the holder at any time beginning on the date that is two months prior to the stated maturity date and ending on the close of business on the second trading-day immediately preceding the maturity date. Upon conversion, we will pay cash and shares of our common stock (or, at our election, cash in lieu of some or all of such common stock), if any. If we undergo a fundamental change as described in the indenture for the 2013 Notes, holders will have the option to require us to purchase all or any portion of their notes for cash at a price equal to 100% of the principal amount of the notes to be purchased plus any accrued and unpaid interest, including any additional interest to, but excluding, the purchase date.

At June 26, 2010, the fair value of our outstanding 2013 Notes was approximately $339,163 based on their quoted market value and no conversion triggers were met.

Effective December 28, 2008, we adopted a newly issued accounting standard for our 2013 Notes which specifies that issuers of convertible debt instruments that may be settled in cash upon conversion should separately account for the liability and equity components in a manner that reflects the entity's nonconvertible debt borrowing rate when interest cost is recognized in subsequent periods. Accordingly, $261,508 of the total proceeds from our $350,000 convertible debt was allocated to the liability component, which represents the estimated fair value of similar debt instruments without the conversion option as of June 12, 2006, the date of issuance. The remaining $88,492 was allocated to the equity component. The debt discount of $88,492 will be amortized to interest expense over the seven-year period from June 2006 to June 2013, the expected life of the instrument. In addition, $8,463 of capitalized interest expense was recorded retrospectively and will amortize over a weighted average life of 32 years. Additionally, approximately $1,903 of deferred financing costs capitalized at the time of issuance was reclassified to equity as equity issuance costs and will not be amortized to interest expense. As a result of the establishment of the debt discount as of the date of issuance, the non-current deferred tax asset relating to the original issue discount has been reduced by $36,437 as of the date of issuance by offsetting additional paid in capital.

As of June 26, 2010, $42,282 of debt discount remained and will be amortized over 12 quarters. As of June 26, 2010 and December 26, 2009, the equity component of our convertible debt was $88,492. Interest expense related to our convertible debt of $3,182 and $2,976 for the quarters ended June 26, 2010 and June 27, 2009, respectively, and for the six months ended June 26, 2010 and June 27, 2009 of $6,315 and $5,906, respectively, yielded an effective interest rate of 6.93% on the liability component.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

In addition, $1,969 and $3,937 of contractual interest expense was recognized on our convertible debt during the three and six months ended June 26, 2010 and $1,969 and $3,937 of contractual interest expense was recognized on our convertible debt during the three and six months ended June 27, 2009.

Principal maturities of existing debt which excludes unamortized debt discount for the periods set forth in the table below are as follows:

We have capital leases for equipment. These leases are capitalized using interest rates considered appropriate at the inception of each lease. Capital lease obligations amounted to $115 and $210 at June 26, 2010 and December 26, 2009, respectively.

Basic earnings per share for the three and six months ended June 26, 2010 and June 27, 2009 were computed by dividing earnings available to common shareowners for these periods by the weighted average number of common shares outstanding in the respective periods adjusted for contingently issuable shares. The weighted average number of common shares outstanding for the three and six months ended June 26, 2010 and June 27, 2009 has been adjusted to include common stock equivalents for the purpose of calculating diluted earnings per share for these periods.

Options to purchase 4,492,355 shares and 6,332,469 shares were outstanding in each of the three respective months ended June 26, 2010 and June 27, 2009, but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive. Options to purchase 4,492,840 and 4,388,779 shares were outstanding in each of the respective six months ended June 26, 2010 and June 27, 2009, but were not included in computing diluted earnings per share because their inclusion would have been anti-dilutive.

Basic weighted average shares outstanding for the three and six months ended June 26, 2010 and June 27, 2009 excluded the weighted average share impact of 979,511 and 1,033,119, respectively, of non-vested fixed restricted stock awards.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

The following table illustrates the reconciliation of the numerator and denominator in the computations of the basic and diluted earnings per share:

The sum of our quarterly earnings per share does not necessarily equal our earnings per share for the six months ended June 26, 2010 and June 27, 2009 due to rounding.

On July 29, 2010, our Board of Directors authorized a $500,000 stock repurchase program. We are currently exploring alternatives for timely execution. The stock purchases may be made from time to time through a variety of methods, including open market repurchases such as block trades, 10b5-1 plans or otherwise in compliance with Rule 10b-18 of the federal securities laws and/or privately negotiated transactions. Funds for the repurchases are expected to come from cash on hand, cash generated by operations, our existing credit facilities or other financings. We have previously repurchased approximately 11 million shares under our prior $600,000 stock repurchase authorization which has been canceled.

Share repurchases made during the three and six months ended June 26, 2010 and June 27, 2009 as part of the share repurchase program were as follows:

Additionally, our 2000 Incentive Plan and 2007 Incentive Plan permit the netting of common stock upon vesting of restricted stock awards in order to satisfy individual tax withholding requirements. During the six months ended June 26, 2010 and June 27, 2009, we acquired 78,626 shares for $2,965

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

and 58,282 shares for $1,483, respectively, as a result of such withholdings. During the quarters ended June 26, 2010 and June 27, 2009, we acquired 1,904 shares for $70 and 2,794 shares for $78, respectively.

The timing and amount of any future repurchases will depend on market conditions and corporate considerations.

Separately and concurrently with the pricing of the 2013 Notes, we issued warrants for approximately 7.2 million shares of our common stock. The warrants give the holders the right to receive, for no additional consideration, cash or shares (at our option) with a value equal to the appreciation in the price of our shares above $59.925, and expire between September 13, 2013 and January 22, 2014 over 90 equal increments. The total proceeds from the issuance of the warrants were $65,423.

A summary of the changes in equity for the six months ended June 26, 2010 and June 27, 2009 is provided below:

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

The following table provides a reconciliation of the provision for income taxes on the condensed consolidated statements of operations:

Our overall effective tax rate was 31.7% in the second quarter of 2010 and 28.8% in the second quarter of 2009. The increase of 2.9% is primarily attributable to the cost of changing the Company's permanent reinvestment assertion with respect to approximately $27,000 of its non-U.S. earnings during the second quarter of 2010. This cost is offset by benefits recognized during the second quarter of 2010 resulting from changes in mix of earnings from operations, transaction costs deducted in the second quarter of 2010, and an increase in tax rate benefits from the Canadian Scientific Research and Experimental Development credits (SR&ED credits).

During the second quarter of 2010, our unrecognized tax benefits recorded decreased by $1,102 to $20,309 primarily due to ongoing evaluation of uncertain tax positions in the current and prior periods and foreign exchange movement. The amount of unrecognized tax benefits that would impact the effective tax rate favorably if recognized decreased by $1,215 to $15,878 and the amount of accrued interest on unrecognized tax benefits decreased by $313 to $1,553 in the second quarter of 2010.

We conduct business in a number of tax jurisdictions. As a result, we are subject to tax audits in jurisdictions including, but not limited to, the United States, the United Kingdom, Japan, France, Germany and Canada. With few exceptions, we are no longer subject to U.S. and international income tax examinations for years before 2003.

We and certain of our subsidiaries are currently under audit by the German Tax Office and various state tax authorities. We believe that it is reasonably possible that the German audit will conclude within the next twelve months. We do not believe that resolution of this audit will have a material impact on our financial position or results of operations.

Additionally, we are challenging the reassessments received by the Canada Revenue Agency (CRA) with respect to the SR&ED credits claimed in 2003 and 2004 by our Canadian Preclinical Services subsidiary in the Tax Court of Canada (TCC). In the fourth quarter of 2009 and the first quarter of 2010, we filed Notices of Appeal with the TCC and received the Crown's response in the second quarter of 2010. In a related development, during the first quarter of 2010 we received Notices of Reassessment from the Minister of Revenue of Quebec (MRQ) provincial tax authorities with respect to the Quebec Research and Development tax credit. We filed Notices of Objection with the MRQ in the second quarter of 2010. We disagree with the positions taken by the CRA and MRQ with regard to the credits claimed. We believe that it is reasonably possible that we will conclude the controversies with the TCC and MRQ within the next twelve months. We do not believe that resolution of these controversies will have a material impact on our financial position or results of operations. However,

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

pending resolution of the reassessments with the TCC, it is possible that the CRA and MRQ will propose similar adjustments for later years.

The Company believes it has appropriately provided for all unrecognized tax benefits.

During the second quarter of 2010, we decided to repatriate approximately $27,000 of the earnings of our non-U.S. subsidiaries that were previously considered to be permanently reinvested. This change in assertion resulted in additional U.S. Federal, state and foreign tax expense of approximately $2,700 in the second quarter of 2010. All remaining undistributed earnings of our non-U.S. subsidiaries remain permanently reinvested as of the end of the second quarter 2010.

The following table provides the components of net periodic benefit cost for our defined benefit plans:

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

The estimated fair value of our stock-based awards, less expected forfeitures, is amortized over the awards' vesting period on a straight-line basis. The following table presents stock-based compensation included in our consolidated statements of operations:

We did not capitalize any stock-based compensation related costs for the quarters or the six months ended June 26, 2010 and June 27, 2009.

The fair value of stock-based awards granted in 2010 and 2009 were estimated on the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:

The following table summarizes the stock option activity in the equity incentive plans for the six months ended June 26, 2010:

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

As of June 26, 2010, the unrecognized compensation cost related to 3,220,152 unvested stock options expected to vest was $28,540. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 35 months.

The total intrinsic value of options exercised during the three and six months ended June 26, 2010 was $653 and $1,141, respectively. The total intrinsic value of options exercised during the three and six months ended June 27, 2009 was $68 and $61, respectively. Intrinsic value is defined as the difference between the market price on the date of exercise and the grant date price. The total amount of cash received from the exercise of options during the six months ended June 26, 2010 and June 27, 2009 was $2,659 and $47, respectively. The actual tax benefit realized for the tax deductions from option exercises totaled $342 and $17 for the six months ending June 26, 2010 and June 27, 2009, respectively.

Stock compensation expense associated with restricted common stock is charged for the market value on the date of grant, less estimated forfeitures, and is amortized over the awards' vesting period on a straight-line basis.

The following table summarizes the restricted stock activity from December 26, 2009 through June 26, 2010:

As of June 26, 2010, the unrecognized compensation cost related to 910,945 shares of unvested restricted stock expected to vest was $28,214. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 32 months. The total fair value of restricted stock grants that vested during the three and six months ended June 26, 2010 was $890 and $9,994, respectively. The total fair value of restricted stock grants that vested during the three and six months ended June 27, 2009 was $1,523 and $10,515, respectively.

During the three months ending June 26, 2010 and June 27, 2009, compensation expense of $105 and $106, respectively, was recorded associated with performance based stock awards. During the six months ending June 26, 2010 and June 27, 2009, compensation expense of $286 and $856, respectively, was recorded associated with these awards.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

Various lawsuits, claims and proceedings of a nature considered normal to our business are pending against us. In the opinion of management, the outcome of such proceedings and litigation currently pending will not materially affect our consolidated financial statements.

We report two segments, Research Models and Services (RMS) and Preclinical Services (PCS). Our RMS segment includes sales of research models, genetically engineered models and services (GEMS), consulting and staffing services, research animal diagnostics, discovery and imaging services, in vitro and avian vaccine services. Our PCS segment includes services required to take a drug through the development process including toxicology, pathology services, bioanalysis, pharmacokinetics and drug metabolism, discovery support, biopharmaceutical services as well as Phase I clinical trials.

The following table presents sales to unaffiliated customers and other financial information by product line segment.

A reconciliation of segment operating income to consolidated operating income is as follows:

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

Other general unallocated corporate expenses consist of various departmental costs including those associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury and investor relations.

Effective December 27, 2009, we adopted an accounting standard update which addressed the accounting for multiple-deliverable arrangements to enable vendors to account for products or services separately rather than as a combined unit. Specifically, this update addresses how to separate deliverables and how to measure and allocate arrangement consideration to one or more units of accounting. The adoption of this update did not have an impact on our consolidated financial statements.

Effective December 27, 2009, we adopted a new accounting standard to improve financial reporting by companies involved with variable interest entities and to provide more relevant and reliable information to users of financial statements. This standard replaces the quantitative-based risks and rewards calculation for determining which reporting entity, if any, has a controlling financial interest in a variable interest entity with an approach focused on identifying which reporting entity has the power to direct the activities of a variable interest entity that most significantly impact the entity's economic performance and (1) the obligation to absorb losses of the entity or (2) the right to receive benefits from the entity. An approach that is expected to be primarily qualitative will be more effective for identifying which reporting entity has a controlling financial interest in a variable interest entity. The amendments in this standard also require additional disclosures about a reporting entity's involvement in variable interest entities, which will enhance the information provided to users of financial statements. The adoption of this update did not have an impact on our consolidated financial statements.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

Effective December 27, 2009, we adopted a new accounting standard for transfers of financial assets to improve the information an entity provides in its financial statements about a transfer of financial assets; the effects of a transfer on its financial position, financial performance, and cash flows; and a transferor's continuing involvement in transferred financial assets. The adoption of this update did not have an impact on our consolidated financial statements.

In January 2010, the FASB issued an accounting standard update to clarify that the stock portion of a distribution to shareholders that allows them to elect to receive cash or stock with a potential limitation on the total amount of cash that all shareholders can elect to receive in the aggregate is considered a share issuance that is reflected in earnings per share prospectively and is not a stock dividend. This update was effective for us on December 27, 2009 and had no impact on our consolidated financial statements.

In January 2010, the FASB issued an accounting standard update to address accounting and reporting by an entity that experiences a decrease in ownership in a subsidiary. This update was effective for us on December 27, 2009 and had no impact on our consolidated financial statements.

In January 2010, the FASB issued an accounting standard update that requires new disclosures related to fair value measurements. A reporting entity should disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and describe the reasons for the transfers. In addition, in the reconciliation for fair value measurements using significant unobservable inputs (Level 3), an entity should present separately information about purchases, sales, issuances and settlements on a gross basis rather than as one net number. This update also clarifies existing disclosures by requiring fair value measurement disclosures for each class of assets and liabilities as well as disclosures about inputs and valuation techniques for fair value measurements that fall into Level 2 or Level 3. This update also includes conforming amendments to the guidance on employers' disclosures about postretirement benefit plans that changes the terminology from major categories of assets to classes of assets. This update was effective for us on December 27, 2009 and has increased the fair value disclosures made in our consolidated financial statements.

In February 2010, the FASB issued an accounting standard update to eliminate inconsistencies and outdated provisions in U.S. GAAP and provided needed clarifications. The clarification of guidance on embedded derivatives and hedging was effective for us on December 27, 2009 and had no impact on our consolidated financial statements. The amendments to guidance on accounting for income taxes in a reorganization was effective for reorganizations on or after December 28, 2008 and had no impact on our consolidated financial statements. All other amendments are effective as of March 28, 2010 and had no impact on our consolidated financial statements.

In February 2010, the FASB issued an accounting standard update to amend required subsequent events disclosure and eliminate potential conflict with SEC guidance. Specifically, an entity that is an SEC filer is no longer required to disclose the date through which subsequent events have been evaluated. This update was effective for us on December 27, 2009 and had no impact on our consolidated financial statements.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED INTERIM
FINANCIAL STATEMENTS (Continued)

In February 2010, the FASB issued an accounting standard update to defer consolidation requirements for an entity's interest in an investment company. This update was effective for us on December 27, 2009 and had no impact on our consolidated financial statements.

In March 2010, the FASB issued an accounting standard update for entities that enter into contracts containing an embedded credit derivative feature. This update is effective for us on June 27, 2010 and has had no impact on our consolidated financial statements.

In April 2010, the FASB issued an accounting standard update to provide guidance on defining a milestone in regards to revenue recognition, and for determining whether the milestone method of revenue recognition is appropriate. An entity can recognize consideration that is contingent upon achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone meets all the criteria to be considered substantive. Determining whether a milestone is substantive is a matter of judgment made at the inception of the arrangement. The amendment will be effective for us on December 26, 2010.

On July 29, 2010, we signed a Mutual Termination of Acquisition Agreement (termination agreement) with WuXi PharmaTech (Cayman) Inc. (WuXi) to terminate our previously announced acquisition agreement. The termination agreement provides for us to pay WuXi a $30,000 breakup fee for full satisfaction of the parties' obligations under the acquisition agreement and includes mutual releases of any claims and liabilities arising out of or relating to the acquisition agreement. As a result of the termination of the acquisition agreement, the special meeting of Charles River stockholders to be held on August 5, 2010 has been canceled.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion should be read in conjunction with our condensed consolidated financial statements and the related notes.

We are a leading global provider of solutions that advance the drug discovery and development process, including research models and associated services and outsourced preclinical services. We provide our products and services to global pharmaceutical and biotechnology companies, as well as government agencies, leading hospitals and academic institutions throughout the world in order to bring drugs to market faster and more efficiently. Our broad portfolio of products and services enables our customers to reduce costs, increase speed to market and enhance their productivity and effectiveness in drug discovery and development. We have built upon our core competency of laboratory animal medicine and science (research model technologies) to develop a diverse and growing portfolio of regulatory compliant preclinical services which address drug discovery and development in the preclinical arena. We have been in business for over 60 years and currently operate approximately 70 facilities in 16 countries worldwide.

Market factors which existed in prior years continue to negatively impact our results. These market factors include: measured spending by major pharmaceutical and biotechnology companies due to the impact of the slower economy; significant impact from consolidations in the pharmaceutical and biotechnology industry; delays in customer decisions and commitments; tight cost constraints by our customers and recognition of excess preclinical capacity within our industry which resulted in pricing pressure; a focus on late-stage (human) testing as customers endeavor to bring drugs to market; and the impact of healthcare reform initiatives. All of these ongoing factors contributed to demand uncertainty and impacted sales in 2010. As we look forward, we continue to anticipate market demand, particularly for Preclinical Services, will begin to ramp up as our customers reinvigorate their drug development efforts and continue to employ methods to improve the effectiveness and cost efficiency of their drug development pipelines, as well as complete consolidations. We believe they will increase their focus on strategic outsourcing, which will drive demand for the services we provide. We believe that the long-term drivers for our business as a whole will primarily emerge from our customers' continued demand for research models and services and regulatory compliant preclinical services, which are essential to the drug development process. During this period of market uncertainty, we aligned our Preclinical Services (PCS) business and our sales and marketing organization to better support market requirements. We completed the sales and marketing reorganization in 2010. We have continued to exercise tight control of discretionary spending and continue our process improvement initiatives including the Lean Six Sigma program to drive further efficiencies in our organization. We have also focused on the roll out of our ERP system: we completed the roll out in the U.S. at the beginning of 2010 and in our PCS Canada and Scotland locations in the third quarter of the year. Our decision to suspend operations at our PCS facility in Shrewsbury, Massachusetts during 2010 is expected to result in a leaner infrastructure while providing sufficient capacity and flexibility to accommodate customer demand in the future. As a result of our decision to suspend operations in Shrewsbury, we recorded a charge for severance costs of $4.8 million in the first half of 2010.

On July 29, 2010, we signed a Mutual Termination of Acquisition Agreement (termination agreement) with WuXi PharmaTech (Cayman) Inc. (WuXi) to terminate our previously announced acquisition agreement. The termination agreement provides for us to pay WuXi a $30 million breakup fee for full satisfaction of the parties' obligations under the acquisition agreement and includes mutual releases of any claims and liabilities arising out of or relating to the acquisition agreement. As a result of the termination of the acquisition agreement, the special meeting of Charles River stockholders to be held on August 5, 2010 has been canceled.

On July 29, 2010, our Board of Directors authorized a $500 million stock repurchase program. We are currently exploring alternatives for timely execution. The stock purchases may be made from time to time through a variety of methods, including open market repurchases such as block trades, 10b5-1 plans or otherwise in compliance with Rule 10b-18 of the federal securities laws and/or privately negotiated transactions. Funds for the repurchases are expected to come from cash on hand, cash generated by operations, our existing credit facilities or other financings. We have previously repurchased approximately 11 million shares under our prior $600 million stock repurchase authorization which has been canceled.

Total net sales during the second quarter of 2010 were $292.1 million, a decrease of 5.2% over the same period last year. The sales decrease was the result of lower pricing for PCS and slower demand for Research Models and Services (RMS), due to reduced biopharmaceutical spending partially offset by foreign exchange and the impact of the acquisitions in 2009. The effect of foreign currency translation decreased sales by 0.1%. Our gross margin decreased to 34.4% of net sales, compared to 37.1% of net sales for the second quarter of 2009, due primarily to the impact of our lower sales. Our operating income for the second quarter of 2010 was $28.2 million compared to $50.7 million for the second quarter of 2009, a decrease of 44.3%. The operating margin was 9.7% for the second quarter of 2010, compared to 16.4% for the second quarter of 2009.

Our net income attributable to common shareholders was $14.5 million for the three months ended June 26, 2010, compared to $34.2 million for the three months ended June 27, 2009. Diluted earnings per share for the second quarter of 2010 were $0.22, compared to $0.52 for the second quarter of 2009.

Total net sales during the six months ended June 26, 2010 were $589.4 million, a decrease of 3.3% over the same period last year. The sales decrease was due primarily to lower pricing for PCS and slower demand for RMS. The effect of foreign currency translation had a positive impact on sales growth of 1.6%. Our gross margin decreased to 34.0% of net sales for the six months ended June 26, 2010, compared to 36.5% of net sales for the first six months of 2009, due primarily to the impact of our lower sales and severance costs. Our operating income for the six months ended June 26, 2010 was $57.7 million compared to $90.6 million for the six months ended June 27, 2009, a decrease of 36.3%. Our operating margin was 9.8% for the six months ended June 26, 2010 compared to 14.9% for the prior year.

Net income attributable to common shareholders was $31.8 million for the six months ended June 26, 2010 compared to $59.6 million for the six months ended June 27, 2009. Diluted earnings per share from continuing operations for the first six months of 2010 were $0.48 compared to $0.91 for the first six months of 2009.

We report two segments: RMS and PCS, which reflect the manner in which our operating units are managed.

Our RMS segment, which represented 57.2% of net sales in the second quarter of 2010, includes sales of research models, genetically engineered models and services (GEMS), research animal diagnostics services (RADS), discovery and imaging services (DIS), consulting and staffing services (CSS), vaccine support and In Vitro. Net sales for this segment increased 0.9% compared to the second quarter of 2009, due to the addition of Cerebricon and Piedmont Research Center, which we acquired in 2009 and favorable In Vitro sales, partially offset by lower large model shipments, lower small model sales and unfavorable foreign currency translation of 0.9%. We experienced decreases in both the gross and operating margin percentages (to 42.7% from 43.0% and to 28.3% from 30.7%, respectively), due mainly to a greater increase in fixed costs relative to the increase in sales.

Sales on a year to date basis for our RMS business segment increased 3.7% compared to the first six months of 2009. Operating income on a year to date basis was $97.2 million compared to

$98.3 million, a decrease of $1.1 million, or 1.1%, from the same period last year. Operating income for the first six months as a percent of net sales decreased to 28.7% compared to 30.1% for the same period last year.

Our PCS segment, which represented 42.8% of net sales in the second quarter of 2010, includes services required to take a drug through the development process including discovery support, toxicology, pathology, biopharmaceutical, bioanalysis, pharmacokinetics and drug metabolism services as well as Phase I clinical trials. Sales for this segment decreased 12.3% compared to the second quarter of 2009. The sales decrease was driven by reduced biopharmaceutical spending, partially offset by favorable foreign currency translation which increased sales by 0.9%. We experienced decreases in both the PCS gross and operating margin percentages (to 23.2% from 30.4% and to 3.8% from 11.5%, respectively), mainly as a result of a greater proportion of short term as well as less complex studies which resulted in an unfavorable service mix and the continued impact of lower prices partially offset by cost savings actions.

Sales on a year to date basis for our PCS segment decreased 11.5% over the same period last year. Operating income for the first six months decreased to 1.8% of net sales, compared to 9.5% for the first six months of 2009.

Our unallocated corporate headquarters cost increased to $23.8 million in the second quarter of 2010, from $16.5 million in the second quarter of 2009, due mainly to increased costs related to the evaluation of acquisitions and the roll out of our ERP system.

Three Months Ended June 26, 2010 Compared to Three Months Ended June 27, 2009

Net Sales. Net sales for the three months ended June 26, 2010 were $292.1 million, a decrease of $16.1 million, or 5.2%, from $308.2 million for the three months ended June 27, 2009.

Research Models and Services. For the three months ended June 26, 2010, net sales for our RMS segment were $167.1 million, an increase of $1.4 million, or 0.9%, from $165.7 million for the three months ended June 27, 2009, due to the acquisition of Cerebricon and Piedmont Research Center during 2009 and favorable In Vitro sales, offset by unfavorable foreign currency translation of 0.9%, and lower large model shipments and small model sales.

Preclinical Services. For the three months ended June 26, 2010, net sales from our PCS segment were $125.0 million, a decrease of $17.5 million, or 12.3%, from $142.5 million for the three months ended June 27, 2009. The decrease in PCS sales was primarily due to lower pricing for preclinical services as well as a greater proportion of short term as well as less complex studies and lower Phase I sales, partially offset by favorable foreign currency translation which increased our net sales by 0.9%.

Cost of Products Sold and Services Provided. Cost of products sold and services provided during the second quarter of 2010 was $191.7 million, a decrease of $2.0 million, or 1.0%, from $193.7 million during the second quarter of 2009. Cost of products sold and services provided during the three months ended June 26, 2010 was 65.6% of net sales, compared to 62.9% during the three months ended June 27, 2009.

Research Models and Services. Cost of products sold and services provided for RMS during the second quarter of 2010 was $95.8 million, an increase of $1.3 million, or 1.4%, compared to $94.5 million in 2009. Cost of products sold and services provided for the three months ended June 26, 2010 increased to 57.3% of net sales compared to 57.0% of net sales for the three months ended June 27, 2009. The increase in cost as a percentage of sales was due to the impact of lower sales on our fixed costs base.

Preclinical Services. Cost of services provided for the PCS segment during the second quarter of 2010 was $95.9 million, a decrease of $3.3 million, or 3.3%, compared to $99.2 million in 2009. Cost of

products sold and services provided as a percentage of net sales was 76.8% during the three months ended June 26, 2010, compared to 69.6% for the three months ended June 27, 2009. The increase in cost of products sold and services provided as a percentage of net sales was primarily due to a greater proportion of short-term as well as less complex studies which resulted in an unfavorable mix, and the continued impact of lower prices partially offset by cost savings actions.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended June 26, 2010 were $66.2 million, an increase of $9.7 million, or 16.9%, from $56.5 million for the three months ended June 27, 2009. Selling, general and administrative expenses during the second quarter of 2010 were 22.6% of net sales compared to 18.4% of net sales during the second quarter of 2009.

Research Models and Services. Selling, general and administrative expenses for RMS for the second quarter of 2010 were $22.8 million, an increase of $4.1 million, or 22.6%, compared to $18.7 million in 2009. Selling, general and administrative expenses increased as a percentage of sales to 13.6% for the three months ended June 26, 2010 from 11.2% for the three months ended June 27, 2009. The increase in selling, general and administrative expenses as a percent of sales was primarily due to the reinstatement of wage increases coupled with larger allocations of corporate Marketing and IT costs.

Preclinical Services. Selling, general and administrative expenses for the PCS segment during the second quarter of 2010 were $19.6 million, a decrease of $1.7 million, or 8.7%, compared to $21.3 million during the second quarter of 2009. Selling, general and administrative expenses for the three months ended June 26, 2010 increased to 15.7% of net sales, compared to 15.1% of net sales for the three months ended June 27, 2009 due mainly to lower sales.

Unallocated Corporate Overhead. Unallocated corporate overhead, which consists of various costs primarily related to activities centered at our corporate headquarters, such as compensation (including stock-based compensation), information systems, compliance and facilities expenses associated with our corporate, administration and professional services functions was $23.8 million during the three months ended June 26, 2010, compared to $16.5 million during the three months ended June 27, 2009. The increase was due primarily to costs related to the evaluation of acquisitions and ERP costs partially offset by cost savings.

Amortization of Other Intangibles. Amortization of other intangibles for the three months ended June 26, 2010 was $6.0 million, a decrease of $1.3 million, from $7.3 million for the three months ended June 27, 2009. Amortization expense decreased as a percentage of sales to 2.1% for the three months ended June 26, 2010 from 2.3% for the three months ended June 27, 2009.

Research Models and Services. In the second quarter of 2010, amortization of other intangibles for our RMS segment was $1.3 million, a decrease of $0.4 million from $1.7 million in the second quarter of 2009.

Preclinical Services. For the three months ended June 26, 2010, amortization of other intangibles for our PCS segment was $4.7 million, a decrease of $0.9 million from $5.6 million for the three months ended June 27, 2009.

Operating Income. Operating income for the quarter ended June 26, 2010 was $28.2 million, a decrease of $22.5 million, or 44.3%, from $50.7 million for the quarter ended June 27, 2009. Operating income as a percentage of net sales for the three months ended June 26, 2010 was 9.7% compared to 16.4% for the three months ended June 27, 2009.

Research Models and Services. For the second quarter of 2010, operating income for our RMS segment was $47.2 million, a decrease of $3.6 million, or 7.1%, from $50.8 million in 2009. Operating

income as a percentage of net sales for the three months ended June 26, 2010 was 28.3%, compared to 30.7% for the three months ended June 27, 2009. The decrease in operating income as a percent to sales was primarily due to higher selling, general and administrative expenses.

Preclinical Services. For the three months ended June 26, 2010, operating income for our PCS segment was $4.8 million, a decrease of $11.6 million, or 71.1%, from $16.4 million of operating income for the three months ended June 27, 2009. Operating income as a percentage of net sales decreased to 3.8% compared to 11.5% of net sales in 2009. The decrease in operating income as a percentage of net sales was primarily due to lower pricing and the mix of studies.

Interest Expense. Interest expense for the second quarter of 2010 was $7.1 million compared to $5.4 million during the second quarter of 2009. The increase was due to increased interest expense on the convertible debt and reduced capitalized interest, as well as the accrual of a commitment fee related to the financing for the WuXi acquisition, partially offset by lower debt balances and lower interest rates on outstanding debt.

Interest Income. Interest income for the second quarter of 2010 was $0.3 million, compared to $0.4 million during the second quarter of 2009 due primarily to lower invested funds and lower interest rates.

Income Taxes. Income tax expense for the three months ended June 26, 2010 was $6.5 million, a decrease of $7.1 million compared to $13.6 million for the three months ended June 27, 2009. Our effective tax rate was 31.7% for the second quarter of 2010, compared to 28.8% for the second quarter of 2009. The increase in the effective tax rate for the three months ended June 26, 2010 was primarily due to the cost accrued in the second quarter of 2010 to repatriate approximately $27 million of non-U.S. earnings that were previously considered to be permanently reinvested. This cost was partially offset by benefits resulting from changes in the mix of earnings from operations, transaction costs deducted in the second quarter of 2010, and an increase in tax rate benefits from Canadian tax credits.

Net income attributable to common shareowners. Net income attributable to common shareowners for the quarter ended June 26, 2010 was $14.5 million, a decrease of $19.7 million from $34.2 million for the quarter ended June 27, 2009.

Net Sales. Net sales for the six months ended June 26, 2010 were $589.4 million, a decrease of $20.3 million, or 3.3%, from $609.7 million for the six months ended June 27, 2009.

Research Models and Services. For the six months ended June 26, 2010, net sales for our RMS segment were $339.3 million, an increase of $12.1 million, or 3.7%, from $327.2 million for the six months ended June 27, 2009. Favorable foreign currency translation increased sales growth by approximately 1.0%. Lower model sales were partially offset by the addition of Cerebricon and Piedmont Research Center.

Preclinical Services. For the six months ended June 26, 2010, net sales for our PCS segment were $250.1 million, a decrease of $32.4 million, or 11.5%, compared to $282.5 million for the six months ended June 27, 2009. The decrease in PCS sales was primarily due to reduced biopharmaceutical spending and pricing pressure and lower Phase I sales. Favorable foreign currency increased sales growth by 2.4%.

Cost of Products Sold and Services Provided. Cost of products sold and services provided for the six months ended June 26, 2010 was $389.1 million, an increase of $2.1 million, or 0.6%, from $387.0 million for the six months ended June 27, 2009. Cost of products sold and services provided for the six months ended June 26, 2010 was 66.0% of net sales, compared to 63.5% for the six months ended June 27, 2009.

Research Models and Services. Cost of products sold and services provided for RMS for the six months ended June 26, 2010 was $193.7 million, an increase of $6.0 million, or 3.2%, compared to $187.7 million for the six months ended June 27, 2009. Cost of products sold and services provided as a percentage of net sales for the six months ended June 26, 2010 was 57.1% compared to the six months ended June 27, 2009 at 57.4% of net sales. The decrease in cost as a percentage of sales was due to fixed costs with increased sales.

Preclinical Services. Cost of services provided for the PCS segment for the six months ended June 26, 2010 was $195.4 million, a decrease of $3.9 million, or 2.0%, compared to $199.3 million for the six months ended June 27, 2009. Cost of services provided as a percentage of net sales was 78.1% for the six months ended June 26, 2010, compared to 70.6% for the six months ended June 27, 2009. The increase in cost of products sold and services provided as a percentage of net sales was primarily due to lower pricing and severance costs.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the six months ended June 26, 2010 were $129.4 million, an increase of $10.7 million, or 8.9%, from $118.7 million for the six months ended June 27, 2009. Selling, general and administrative expenses for the six months ended June 26, 2010 were 21.9% of net sales compared to 19.5% of net sales for the six months ended June 27, 2009. The increase in selling, general and administrative expenses as a percent of sales was primarily due to the lower sales.

Research Models and Services. Selling, general and administrative expenses for RMS for the six months ended June 26, 2010 were $44.7 million, an increase of $6.1 million, or 15.9%, compared to $38.6 million for the six months ended June 27, 2009. Selling, general and administrative expenses increased as a percentage of sales to 13.2% for the six months ended June 26, 2010 from 11.8% for the six months ended June 27, 2009. The increase in selling, general and administrative expenses as a percent of sales was primarily due to the reinstatement of wage increases coupled with larger allocations of corporate Marketing and IT costs.

Preclinical Services. Selling, general and administrative expenses for the PCS segment for the six months ended June 26, 2010 were $40.7 million, a decrease of $4.8 million, or 10.6%, compared to $45.5 million for the six months ended June 27, 2009. Selling, general and administrative expenses for the six months ended June 26, 2010 increased to 16.3% of net sales compared 16.1% for the six months ended June 27, 2009, due mainly to lower sales.

Unallocated Corporate Overhead. Unallocated corporate overhead, which consists of various costs primarily related to activities centered at our corporate headquarters, such as compensation (including stock-based compensation), information systems, compliance and facilities expenses associated with our corporate, administration and professional services functions was $44.0 million for the six months ended June 26, 2010, compared to $34.6 million for the six months ended June 27, 2009. The increase in unallocated corporate overhead during the first half of 2010 was due primarily to costs related to the evaluation of acquisitions and ERP costs, partially offset by cost savings.

Amortization of Other Intangibles. Amortization of other intangibles for the six months ended June 26, 2010 was $13.2 million, a decrease of $0.2 million, from $13.4 million for the six months ended June 27, 2009.

Research Models and Services. For the six months of 2010, amortization of other intangibles for our RMS segment was $3.7 million, an increase of $1.1 million from $2.6 million for the six months ended June 27, 2009. Amortization expense increased as a percentage of sales to 1.1% for the six months ended June 26, 2010 from 0.8% for the six months ended June 27, 2009 due the acquisitions of Cerebricon, Piedmont Research Center and Medical Supply Company in 2009.

Preclinical Services. For the six months ended June 26, 2010, amortization of other intangibles for our PCS segment was $9.5 million, a decrease of $1.3 million from $10.8 million for the six months ended June 27, 2009.

Operating Income. Operating income for the six months ended June 26, 2010 was $57.7 million, a decrease of $32.9 million, or 36.3%, from $90.6 million for the six months ended June 27, 2009. Operating income for the six months ended June 26, 2010 was 9.8% of net sales, compared to 14.9% of net sales for the six months ended June 27, 2009.

Research Models and Services. For the six months ended June 26, 2010, operating income for our RMS segment was $97.2 million, a decrease of $1.1 million, or 1.1%, from $98.3 million for the six months ended June 27, 2009. Operating income as a percentage of net sales for the six months ended June 26, 2010 was 28.7%, compared to 30.1% for the six months ended June 27, 2009. The decrease in operating income as a percentage of sales was primarily due to higher selling, general and administrative expenses.

Preclinical Services. For the six months ended June 26, 2010, operating income for our PCS segment was $4.5 million, a decrease of $22.4 million, or 83.4%, from $26.9 million for the six months ended June 27, 2009. Operating income as a percentage of net sales for the six months ended June 26, 2010 decreased to 1.8%, compared to 9.5% of net sales for the six months ended June 27, 2009. The decrease in operating income as a percentage of net sales was primarily due to lower sales resulting from lower pricing.

Interest Expense. Interest expense for the six months ended June 26, 2010 was $13.1 million, compared to $10.6 million for the six months ended June 27, 2009. The increase was due to increased interest expense on the convertible debt and reduced capitalized interest, as well as the accrual of a commitment fee related to the financing for the WuXi acquisition, partially offset by lower debt balances and lower interest rates on outstanding debt.

Interest Income. Interest income for the six months ended June 26, 2010 was $0.7 million compared to $1.0 million for the six months ended June 27, 2009, primarily due to lower cash balances and lower interest rates on invested funds.

Income Taxes. Income tax expense for the six months ended June 26, 2010 was $13.0 million, a decrease of $10.8 million compared to $23.8 million for the six months ended June 27, 2009. Our effective tax rate was 29.5% for the six months ended June 26, 2010, compared to 28.9% for the six months ended June 27, 2009. The increase in the effective tax rate for the six months ended June 26, 2010 was primarily due to the cost accrued in the first six months of 2010 to repatriate approximately $27 million of non-U.S. earnings that were previously considered to be permanently reinvested. This cost was partially offset by benefits resulting from changes in mix of earnings from operations, transaction costs deducted in the first six months of 2010, and an increase in tax rate benefits from Canadian tax credits.

Net Income attributable to common shareowners. Net income attributable to common shareowners for the six months ended June 26, 2010 was $31.8 million, compared to the six months ended June 27, 2009 of $59.6 million.

The following discussion analyzes liquidity and capital resources by operating, investing and financing activities as presented in our condensed consolidated statements of cash flows.

Our principal sources of liquidity have been our cash flow from operations, our marketable securities and our revolving line of credit arrangements.

As of June 26, 2010, we had $28.3 million in marketable securities with $11.7 million in time deposits and $16.5 million in auction rate securities rated AAA by a major credit rating agency. Our auction rate securities are guaranteed by U.S. federal agencies. In June, we received notice of a full call on certain of our auction rate securities at par value of $5.5 million and received the proceeds in early July. The current overall credit concerns in the capital markets as well as the failed auction status of these securities have impacted our ability to liquidate our auction rate securities. If the auctions for the securities we own continue to fail, the investment may not be readily convertible to cash until a future auction of these investments is successful. Based on our ability to access our cash and other short-term investments, our expected operating cash flows and other sources of cash, we do not anticipate the current lack of liquidity on these investments will affect our ability to operate our business as usual.

In 2006, we issued $350.0 million of 2.25% Convertible Senior Notes (the 2013 Notes) due in 2013. At June 26, 2010, the fair value of our outstanding 2013 Notes was approximately $339.2 million based on their quoted market value. During the second quarter of 2010, no conversion triggers were met.

On July 29, 2010, we signed a Mutual Termination of Acquisition Agreement (termination agreement) with WuXi PharmaTech (Cayman) Inc. (WuXi) to terminate our previously announced acquisition agreement. The termination agreement provides for us to pay WuXi a $30 million breakup fee for full satisfaction of the parties' obligations under the acquisition agreement and includes mutual releases of any claims and liabilities arising out of or relating to the acquisition agreement. As a result of the termination of the acquisition agreement, the special meeting of Charles River stockholders to be held on August 5, 2010 has been canceled.

Cash and cash equivalents totaled $219.1 million at June 26, 2010, compared to $182.6 million at December 26, 2009.

Net cash provided by operating activities for the six months ending June 26, 2010 and June 27, 2009 was $83.8 million and $107.3 million, respectively. The decrease in cash provided by operations was primarily due to changes in accounts receivable and lower earnings. Our days sales outstanding (DSO) increased to 51 days as of June 26, 2010 compared to 43 days as of December 26, 2009, and 41 days as of June 27, 2009. The increase in our DSO was primarily driven by slower collections and decreased deferred revenue. Our allowance for doubtful accounts was $5.2 million as of June 26, 2010 compared to $5.0 million as of December 27, 2009 and $4.6 million as of June 27, 2009. Our DSO includes deferred revenue as an offset to accounts receivable in the calculation.

Net cash provided by (used in) investing activities for the six months ending June 26, 2010 and June 27, 2009 was $23.5 million and ($149.0) million, respectively. Our capital expenditures during the first six months of 2010 were $17.7 million, of which $11.2 million was related to RMS and $6.5 million to PCS. For 2010, we project capital expenditures to be in the range of $60-$70 million. We anticipate that future capital expenditures will be funded by operating activities, marketable securities and existing credit facilities. During the first half of 2010, we sold $56.5 million of marketable securities.

Net cash used in financing activities for the six months ending June 26, 2010 and June 27, 2009 was $63.2 million and $44.4 million, respectively. Payments on long-term debt and revolving credit

agreements were $63.7 million and $17.3 million for the six months ending June 26, 2010 and June 27, 2009, respectively. During the first six months of 2009, we purchased $45.2 million of treasury stock.

categories of assets to classes of assets. This update was effective for us on December 27, 2009 and has increased the fair value disclosures made in our consolidated financial statements.

The conversion features of our 2013 Notes are equity-linked derivatives. As such, we recognize these instruments as off-balance sheet arrangements. Because the conversion features associated with these notes are indexed to our common stock and classified in stockholders' equity, these instruments are not accounted for as derivatives.

Certain of our financial instruments are subject to market risks, including interest rate risk and foreign currency exchange rates. We generally do not use financial instruments for trading or other speculative purposes.

We have entered into two credit agreements, the amended and restated credit agreement dated July 31, 2006 (credit agreement) and the $50 million credit agreement. Our primary interest rate exposure results from changes in LIBOR or the base rates which are used to determine the applicable interest rates under our term loans and revolving credit facility in the credit agreement and in the $50 million credit agreement. Our potential additional interest expense over one year that would result from a hypothetical, instantaneous and unfavorable change of 100 basis points in the interest rate

would be approximately $2.8 million on a pre-tax basis. The book value of our debt approximates fair value.

We issued $350 million of the 2013 Notes in a private placement in the second quarter of 2006. The Convertible 2013 Notes bear an interest rate of 2.25%. The fair market value of the outstanding notes was $339.2 million on June 26, 2010.

We operate on a global basis and have exposure to some foreign currency exchange rate fluctuations for our earnings and cash flows. This risk is mitigated by the fact that various foreign operations are principally conducted in their respective local currencies. A portion of the revenue from our foreign operations is denominated in U.S. dollars, with the costs accounted for in their local currencies. We attempt to minimize this exposure by using certain financial instruments, for purposes other than trading, in accordance with our overall risk management and our hedge policy. In accordance with our hedge policy, we designate such transactions as hedges.

During 2010, we have utilized foreign exchange contracts, principally to hedge the impact of currency fluctuations on customer transactions and certain balance sheet items. There were no foreign exchange contracts open as of June 26, 2010.

Based on their evaluation, required by paragraph (b) of Rules 13a-15 or 15d-15, promulgated by the Securities Exchange Act of 1934 , the Company's principal executive officer and principal financial officer have concluded that the Company's disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act are effective as of June 26, 2010 to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired control objectives, and management necessarily was required to apply its judgment in designing and evaluating the controls and procedures. We continually are in the process of further reviewing and documenting our disclosure controls and procedures, and our internal control over financial reporting, and accordingly may from time to time make changes aimed at enhancing their effectiveness and to ensure that our systems evolve with our business.

There were no changes in the Company's internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of the Exchange Act Rules 13a-15 or 15d-15 that occurred during the quarter ended June 26, 2010 that materially affected, or were reasonably likely to materially affect, the Company's internal control over financial reporting except as described below.

At the start of the first quarter of 2010, we implemented the first phase of our new Enterprise Resource Planning System (ERP) which includes all of our United States locations. As a result of the

system changes, several of our internal controls over processes were modified and/or redesigned and included in the scope of management's assessment of its internal controls over financial reporting. This implementation of the ERP is not in response to any identified deficiency or weakness in our internal control over financial reporting and we will continue to implement the ERP in other locations in future phases. We continued the plan roll out for our ERP with the implementation in our PCS Montreal and PCS Scotland locations at the start of the third quarter 2010.

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, "Item 1A. Risk Factors" in our Annual Report on Form 10-K for the year ended December 26, 2009, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results. There have been no material changes to the risk factors set forth in our Annual Report on Form 10-K for the year ended December 26, 2009.

Additionally, the Company's Incentive Plans permit the netting of common stock upon vesting of restricted stock awards in order to satisfy individual tax withholding requirements. Accordingly, during the quarter ended June 26, 2010, the Company acquired 1,904 shares for $0.07 million as a result of such withholdings.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		June 26, 2010		December 26, 2009

Raw materials and supplies		$	14,095	$	15,262
Work in process			18,494		17,178
Finished products			63,982		70,283

	Inventories	$	96,571	$	102,723

		June 26, 2010		December 26, 2009

Prepaid assets		$	24,830	$	21,182
Deferred tax asset			23,987		21,654
Marketable securities			17,228		56,436
Prepaid income tax			7,244		13,846
Restricted cash			416		239

	Other current assets	$	73,705	$	113,357

		June 26, 2010			December 26, 2009

Land		$	39,453		$	39,402
Buildings			747,662			755,607
Machinery and equipment			310,168			319,912
Leasehold improvements			39,522			38,853
Furniture and fixtures			11,383			11,455
Vehicles			5,362			5,595
Computer hardware and software			103,725			53,654
Construction in progress			43,077			86,272

	Total		1,300,352			1,310,750
Less accumulated depreciation			(462,772	)		(445,007	)

Net property, plant and equipment		$	837,580		$	865,743

		June 26, 2010		December 26, 2009

Deferred financing costs		$	3,963	$	3,679
Cash surrender value of life insurance policies			29,139		25,099
Long-term marketable securities			11,045		16,212
Other assets			9,326		10,254

	Other assets	$	53,473	$	55,244

		June 26, 2010		December 26, 2009

Accrued income taxes		$	17,818	$	13,623
Current deferred tax liability			1,011		1,174
Accrued interest and other			340		422

	Other current liabilities	$	19,169	$	15,219

		June 26, 2010		December 26, 2009

Deferred tax liability		$	38,826	$	42,867
Long-term pension liability			29,233		32,516
Accrued Executive Supplemental Life Insurance Retirement Plan and Deferred Compensation Plan			23,479		22,889
Other long-term liabilities			15,581		24,805

	Other long-term liabilities	$	107,119	$	123,077

	June 26, 2010

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Time deposits	$	11,728	$	—	$	—		$	11,728
Auction rate securities		17,475		—		(930	)		16,545

	$	29,203	$	—	$	(930	)	$	28,273

	December 26, 2009

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
Time deposits	$	9,022	$	—	$	—		$	9,022
Mutual fund		47,615		—		(201	)		47,414
Auction rate securities		17,460		—		(1,248	)		16,212

	$	74,097	$	—	$	(1,449	)	$	72,648

	Fair Value Measurements at June 26, 2010 using

	Quoted Prices in Active Markets for Identical Assets Level 1		Significant Other Observable Inputs Level 2		Significant Unobservable Inputs Level 3		Assets at Fair Value
Time deposits	$	—	$	11,728	$	—	$	11,728
Auction rate securities		—		—		16,545		16,545
Fair value of life policies		—		23,779		—		23,779

Total assets	$	—	$	35,507	$	16,545	$	52,052

Contingent consideration		—		—		9,700		9,700

Total liabilities	$	—	$	—	$	9,700	$	9,700

		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

		Six months ended
Auction rate securities		June 26, 2010		June 27, 2009
Beginning balance		$	16,212	$	18,958
Transfers in and/or out of Level 3			—		—
Total gains or losses (realized/unrealized):
	Included in earnings (other expenses)		—		(47	)
	Included in other comprehensive income		333		442
Purchases, issuances and settlements			—		—

Ending balance		$	16,545	$	19,353

		Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

		Six months ended
Contingent Consideration		June 26, 2010		June 27, 2009
Beginning balance		$	9,300	$	—
Transfers in and/or out of Level 3			—		—
Total gains or losses (realized/unrealized):
	Included in (earnings) other expenses		400		—
	Included in other comprehensive income		—		—
Purchases, issuances and settlements			—		—

Ending balance		$	9,700	$	—

		June 26, 2010							December 26, 2009

		Gross Carrying Amount		Accumulated Amortization & Impairment loss			Net Amount		Gross Carrying Amount		Accumulated Amortization & Impairment loss			Net Amount
Goodwill		$	1,213,280	$	(712,695	)	$	500,585	$	1,221,100	$	(712,865	)	$	508,235

Other intangible assets not subject to amortization:
	Research models		3,438		—			3,438		3,438		—			3,438
	PCS in process R&D		14,000		—			14,000		14,000		—			14,000
Other intangible assets subject to amortization:
	Backlog		2,764		(2,014	)		750		2,961		(2,011	)		950
	Customer relationships		307,384		(183,618	)		123,766		313,021		(173,707	)		139,314
	Customer contracts		15,259		(15,259	)		—		15,259		(15,259	)		—
	Trademarks and trade names		5,081		(4,470	)		611		5,081		(4,338	)		743
	Standard operating procedures		657		(657	)		—		657		(643	)		14
	Other identifiable intangible assets		6,882		(5,422	)		1,460		6,935		(5,102	)		1,833

Total other intangible assets		$	355,465	$	(211,440	)	$	144,025	$	361,352	$	(201,060	)	$	160,292

					Adjustments to Goodwill

		Balance at December 26, 2009			Acquisitions		Foreign Exchange/ Other			Balance at June 26, 2010
Research Models and Services
	Gross carrying amount	$	58,734		$	—	$	(1,422	)	$	57,312
	Accumulated amortization		(4,875	)		—		170			(4,705	)
Preclinical Services
	Gross carrying amount		1,162,366			—		(6,398	)		1,155,968
	Accumulated impairment loss		(700,000	)		—		—			(700,000	)
	Accumulated amortization		(7,990	)		—		—			(7,990	)
Total
	Gross carrying amount	$	1,221,100		$	—	$	(7,820	)	$	1,213,280
	Accumulated impairment loss		(700,000	)		—		—			(700,000	)
	Accumulated amortization		(12,865	)		—		170			(12,695	)

		June 26, 2010			December 26, 2009

2.25% Senior convertible debentures:
	Principal	$	349,995		$	349,995
	Unamortized debt discount		(42,282	)		(48,597	)

Net carrying amount of senior convertible debentures			307,713			301,398
Term loan facilities			74,533			100,433
Revolving credit facility			53,000			90,000
Other debt, represents secured and unsecured promissory notes, interest rates ranging from 0% to 5.3% and 0% to 0.5% at June 26, 2010 and December 26, 2009, respectively, maturing between 2010 and 2012			854			792

Total debt			436,100			492,623
Capital leases			115			209

Total debt and capital leases			436,215			492,832
Less: current portion of long-term debt and capital leases			(26,774	)		(35,413	)

Long-term debt and capital leases		$	409,441		$	457,419

Twelve months ending

June 2011		$	26,749
June 2012			101,638
June 2013			349,995
June 2014
June 2015			—

	Total	$	478,382

	Options Granted In:

	2010			2009
Expected life (in years)		4.5			4.5
Expected volatility		34.0	%		25.0	%
Risk-free interest rate		2.35	%		1.86	%
Expected dividend yield		0.0	%		0.0	%
Weighted-average grant date fair value	$	11.96		$	6.13

			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value

Options outstanding as of December 26, 2009	6,216,943		$	37.67
Options granted	1,363,380		$	37.34
Options exercised	(110,582	)	$	24.04
Options canceled	(218,899	)	$	40.86

Options outstanding as of June 26, 2010	7,250,842		$	37.72	4.76 years	$	24,210

Options exercisable as of June 26, 2010	3,788,313		$	40.61	3.83 years	$	8,490

				Weighted Average Grant Date Fair Value

Outstanding December 26, 2009		896,393		$	36.45
	Granted	378,620		$	37.34
	Vested	(264,258	)	$	37.82
	Canceled	(31,244	)	$	36.81

Outstanding June 26, 2010		979,511		$	36.41

		Six Months Ended

		June 26, 2010									June 27, 2009
		Shareowners' Equity			Noncontrolling Interest			Total Equity			Shareowners' Equity			Noncontrolling Interest			Total Equity
Equity, beginning of the period		$	1,375,243		$	(1,419	)	$	1,373,824		$	1,241,286		$	422		$	1,241,708
Components of comprehensive income, net of tax:
	Net income		31,836			(741	)		31,095			59,559			(1,035	)		58,524
	Foreign currency translation adjustment		(25,549	)		(21	)		(25,570	)		15,642			—			15,642
	Amortization of pension, net gain/loss and prior service cost		177			—			177			757			—			757
	Unrealized loss on marketable securities		535			—			535			442			—			442

Total comprehensive income			6,999			(762	)		6,237			76,400			(1,035	)		75,365
	Dividends paid noncontrolling interest		—			(270	)		(270	)		—			—			—
	Tax detriment associated with stock issued under employee compensation plans		(140	)		—			(140	)		(2,433	)		—			(2,433	)
	Issuance of stock under employee compensation plans		2,659			—			2,659			47			—			47
	Exercise of warrants		—			—			—			6			—			6
	Acquisition of treasury shares		(2,965	)		—			(2,965	)		(43,870	)		—			(43,870	)
	Stock-based compensation		14,672			—			14,672			12,133			—			12,133

Equity, end of the period		$	1,396,468		$	(2,451	)	$	1,394,017		$	1,283,569		$	(613	)	$	1,282,956


	10.1		Charles River Laboratories Corporate Officer Separation Plan (revised April 2010). Filed herewith.+
	31.1		Certification of the Principal Executive Officer required by Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Filed herewith.
	31.2		Certification of the Principal Financial Officer required by Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Filed herewith.
	32.1		Certification of the Principal Executive Officer and Principal Financial Officer required by Rule 13a-14(a) or 15d-14(a) of the Exchange Act. Filed herewith.
	101		The following materials from the Form 10-Q for the quarter ended June 26, 2010, formatted in eXtensible Business Reporting Language (XBRL): (i) Condensed Consolidated Statements of Operations, (ii) Condensed Consolidated Balance Sheets, (iii) Condensed Consolidated Statements of Cash Flows, (iv) Condensed Consolidated Statement of Changes in Equity and (v) Notes to Unaudited, Condensed Consolidated Interim Financial Statements.


		CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
August 3, 2010		/s/ JAMES C. FOSTER James C. Foster Chairman, President and Chief Executive Officer
August 3, 2010		/s/ THOMAS F. ACKERMAN Thomas F. Ackerman Corporate Executive Vice President and Chief Financial Officer